COVID-19

Emergency use: check votes, report and meeting presentations

The Collegiate Board unanimously approved a temporary authorization for the emergency use of the CoronaVac and Covishield vaccines.

Published on 17/01/2021 17h29 Updated on 20/01/2021 16h55

Check below the materials used in the meeting of the Board of Directors of Anvisa this Sunday (1/17), which unanimously decided to temporarily authorize the emergency use of the CoronaVac vaccine, developed by the pharmaceutical company Sinovac in partnership with the Butantan Institute, and the Covishield vaccine , produced by the pharmaceutical company Serum Institute of India, in partnership with AstraZeneca / Oxford University / Fiocruz. Check out the materials presented during the meeting below:

- Report - Technical basis for emergency use decision
- CoronaVac Presentation
- Covishield Presentation
- Butantan's risk management plan
- FioCruz's risk management plan
- Butantan Good Manufacturing Practices
- Good Manufacturing Practices of FioCruz
- Opinion Nº 2 / 2021- GPBIO / GGMED / DIRE2 / ANVISA / BUTANTAN
- Opinion Nº 2/2021 -GGFIS / DIRE4 / ANVISA / BUTANTAN
- Opinion Nº 3 / 2021- GIMED / GGFIS / DIRE4 / ANVISA / FIOCRUZ
- Opinion Nº 3 / 2021- GPBIO / GGMED / DIRE2 / ANVISA / FIOCRUZ
- Extract from Dicol's resolution
- First Board Vote
- Second Board Vote (rapporteur)
- Vote Third Board
- Vote Fourth Board
- Vote Fifth Board
- CoronaVac health care package insert

Do you want to know Anvisa news first hand? Follow us on Twitter @anvisa_oficial, Facebook @ AnvisaOficial , Instagram @anvisaoficial and YouTube @anvisaoficial

Category

Health and Health Surveillance

error while rendering plone.belowcontenttitle.contents

Tags: new covid-19 coronavirus vaccine against covid-19 emergency use

Share: